期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
1
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部